Visit a quote page and your recently viewed tickers will be displayed here. The top-performing stocks tend to have a. The developer of treatments for hemophilia and other disorders is now trading at the upper end of the buy zone.

Bioverativ saw a positive improvement to its Relative Strength RS Rating on Tuesday, with an increase from 88 to Bioverativ BIVV and Biohaven Pharmaceuticals BHVN stocks broke out Monday, riding an uptrend in the biotech sector to hit record highs just four months and one month, respectively, after their initial public offerings.

Biogen BIIB spun-off its hemophilia unit into. Kennametal, Bioverativ and Apple highlighted as Zacks Bull and Bear of the Day. Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed. FDA accepts Bioverativ's IND for long-acting hemophilia A candidate.

FDA accepts Bioverativ's IND for long-acting hemophilia A candidate BIVV Late Tuesday, Roche presented data from a head-to-head trial of its drug Alecensa vs.

Bioverativ BIVV Presents At Jefferies Global Healthcare Conference - Slideshow. Regeneron Pharmaceuticals REGN went to the "heart of the debate" on Tuesday, questioning the validity of Amgen's AMGN patent on its LDL cholesterol-busting drug, Repatha, an analyst said following a court hearing. But Wall Street was split Wednesday on where the appeals court process would land. And while Biogen has struggled recently, its spinoff and IPO Bioverativ BIVV may be getting ready to launch a move of its own.

Bioverativ develops therapies to treat hemophilia and other blood disorders, and is beefing up its product pipeline with. The developer of therapies to treat hemophilia and other blood disorders, went public in February and has been climbing steadily higher — clearly outperforming this year's big buzz initial public offering from Snapchat parent Snap SNAP.

ARNC, BIVV, TEP, OPK, CHK, AKAM, DATA. Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV, a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN R half-life extension technology. Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ.

Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics. Bioverativ Appoints Geno J. Bioverativ to Present at the Bank of America Merrill Lynch Healthcare Conference.

Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics. Axsome Received Fast Track Designation for its Treatment of Agitation in Patients with Alzheimer's Disease.

Stock Market Basics - Essential Overview for Penny Stock Investing

Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan. Bioverativ Appoints Tim Harris Executive Vice President, Research and Development. Bioverativ to Report First Quarter Financial Results on May 3, Bioverativ engages in discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorder.

Its product includes Eloctate and Alprolix. The company is headquartered in Cambridge, MA. By using this site you agree to the Terms of ServicePrivacy Policyand Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U. Intraday data delayed at least 15 minutes or per exchange requirements.

Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.

US Europe Asia FX Rates Futures Range 1D 5D 1M 3M 6M 1Y 2Y FTSE 7, Latest News All Times Eastern. Home Investing Quotes Stocks United States BIVV Overview Compare Quotes Stock Screener Earnings Calendar Sectors Nasdaq. Watch list Create BIVV Alert. Jun 21, 9: EDT Real time quote. Advanced Charting 1D 5D 1M 3M 6M YTD 1Y 3Y All. Customize MarketWatch Have Watchlists? Log in to see them here or sign up to get started.

Create Account … or Log In. No Items in Watchlist There are currently no stock market cheat sheets in this Watchlist. Add Ticker to Watchlist. Go to Options derivatives market Watchlist. No Saved Watchlists Create a list of the investments you want to track. Create Watchlist …or try this starter list.

Uh oh Something went wrong while loading Watchlist. No Recent Tickers Visit a quote page and your recently viewed tickers will be displayed here. Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders. Performance 5 Day 8. Recent News MarketWatch Other Dow Jones 15 companies with outsized sales growth and widening profit margins Apr.

Dynasty Nerds - Dynasty Fantasy Football (Rankings - Strategy - Cheat Sheets)

ET by Philip van Doorn. ET by Tomi Kilgore. Recent News Other News Press Releases New Strong Sell Stock options for ceos for June 20th Here are 5 stocks added to the Zacks Rank 5 Strong Sell List today: The top-performing stocks tend to have a Jun.

ET on Investors Business Daily. This exclusive rating Jun. Biotech IPOs Ride Sectorwide Boom To Breakout Monday Bioverativ BIVV and Biohaven Pharmaceuticals BHVN stocks broke out Monday, riding an uptrend in the biotech sector to hit record highs just four months and one month, respectively, after their initial public offerings.

Biogen BIIB spun-off its hemophilia unit into Jun. Kennametal, Bioverativ and Apple highlighted as Zacks Bull and Bear of the Day Kennametal, Bioverativ and Apple highlighted as Zacks Bull and Bear of the Day Jun.

Bear of the Day: Bioverativ BIVV Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed Jun.

Where to Find Value in a Lofty Market Where to Find Value catalog of the best binary options brokers a Lofty Market Jun.

FDA accepts Bioverativ's IND for long-acting hemophilia A candidate FDA accepts Bioverativ's IND for long-acting hemophilia A candidate Jun. ET on Seeking Alpha. FDA accepts Bioverativ's IND for long-acting hemophilia A candidate BIVV FDA accepts Bioverativ's IND for long-acting hemophilia A candidate BIVV Jun. Bioverativ BIVV Presents At Jefferies Global Healthcare Conference - Slideshow Bioverativ BIVV Presents At Jefferies Global Healthcare Conference - Slideshow Jun.

Will Regeneron's Cholesterol-Buster Get Booted In Amgen Battle? Buy Omega Healthcare Insider Transactions Newsletter: Buy Omega Healthcare Jun. Bioverativ develops therapies to is forex trading haram or halal hemophilia and other eex trading days disorders, and is beefing up its product pipeline with Jun.

Monster Insider Purchase Indicates Good Times Ahead Bioverativ: Monster Insider Purchase Indicates Good Times Ahead Jun. Is This Biotech IPO And Biogen Spinoff About To Break Out? The 'Best Balance Sheets' Portfolio: Biogen And Bioverativ The 'Best Balance Sheets' Portfolio: Biogen And Bioverativ Jun.

ARNC, BIVV, TEP, OPK, CHK, AKAM, DATA InsiderInsights. ARNC, BIVV, TEP, OPK, CHK, AKAM, DATA Jun. Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV, a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN R half-life extension technology Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV, a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN R half-life extension technology Jun.

Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ Jun.

ET on PR Newswire - PRF. Bioverativ to Present at the Jefferies Healthcare Conference Bioverativ to Present at the Jefferies Healthcare Conference Jun. ET on BusinessWire - BZX.

Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics May. Bioverativ to Present at the Bank of America Merrill Lynch Healthcare Conference Bioverativ to Present at the Bank of America Merrill Lynch Healthcare Conference May. Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics May.

Axsome Received Fast Track Designation for its Treatment of Agitation in Patients with Alzheimer's Disease Blog Coverage: Axsome Received Fast Track Designation for its Treatment of Agitation in Patients with Alzheimer's Disease May. Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan May.

Bioverativ Reports First Quarter Results Bioverativ Reports First Quarter Results May. Bioverativ Joins in Celebration of World Hemophilia Day Bioverativ Joins in Celebration of World Hemophilia Day Apr. Bioverativ Appoints Tim Harris Executive Vice President, Research and Development Bioverativ Appoints Tim Harris Executive Vice President, Research and Development Apr. Bioverativ to Report First Quarter Financial Results on May 3, Bioverativ to Report First Quarter Financial Results on May 3, Apr.

Technical Reports on Biotech Stocks -- Bioverativ, Pulmatrix, PharmAthene, and Zosano Pharma Mar. Anna Protopapas to Join Bioverativ Board of Directors Mar. Bioverativ to Present at the Cowen and Company 37th Annual Health Care Conference Feb. BIVV to Ring The Nasdaq Stock Market Opening Bell Feb. Bioverativ to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb.

Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology Feb. Analyst Ratings Sell Under Hold Over Buy Number of Ratings 11 Full Ratings. Your Cheat Sheet For Q1 Biotech Earnings Apr. Argus Initiates Bioverativ With Hold Mar. Morgan Stanley Takes A Breather On Biogen, Downgrades Stock Mar.

MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile. Dow Jones Network WSJ. Trending Tickers Powered by AMD 7.